KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Inventory (2021 - 2025)

Novavax has reported Inventory over the past 5 years, most recently at $11.5 million for Q4 2025.

  • Quarterly results put Inventory at $11.5 million for Q4 2025, up 31.96% from a year ago — trailing twelve months through Dec 2025 was $11.5 million (up 31.96% YoY), and the annual figure for FY2025 was $11.5 million, up 31.96%.
  • Inventory for Q4 2025 was $11.5 million at Novavax, down from $13.5 million in the prior quarter.
  • Over the last five years, Inventory for NVAX hit a ceiling of $256.3 million in Q2 2022 and a floor of $8.6 million in Q3 2024.
  • Median Inventory over the past 5 years was $15.8 million (2024), compared with a mean of $44.0 million.
  • Biggest five-year swings in Inventory: skyrocketed 313.47% in 2022 and later plummeted 90.84% in 2023.
  • Novavax's Inventory stood at $8.9 million in 2021, then soared by 313.47% to $36.7 million in 2022, then rose by 13.67% to $41.7 million in 2023, then plummeted by 79.02% to $8.7 million in 2024, then surged by 31.96% to $11.5 million in 2025.
  • The last three reported values for Inventory were $11.5 million (Q4 2025), $13.5 million (Q3 2025), and $10.2 million (Q2 2025) per Business Quant data.